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Abstract 
Intratumoral heterogeneity is ubiquitously present within primary tumors and contributes to 
intractable behaviors such as metastasis and mutability spatiotemporally. Mounting evidence has 
shown that heterogeneous cell populations can adversely affect cell metabolism and metastatic 
potential. The cell’s only fluorescent molecules within the electron transport chain, flavin 
adenine dinucleotide (FAD) and nicotinamide adenine dinucleotide (NADH), can allow the 
quantitation of cell metabolism. We demonstrate the use of the optical redox ratio 
(FAD/(NADH+FAD)) to determine the metabolic behaviors of a heterogeneous panel of cells 
with varying metastatic programs at normal conditions and following acute hypoxia. At normal 
conditions, we reveal an attenuation in the optical redox ratio as metastatic potential decreases, 
not including the non-metastatic cell line. We reveal that reoxygenating the clonogenic cells after 
hypoxia enabled further differences in the optical redox ratio for the highly metastatic (increased 
by 43 ± 9%), semi-metastatic (increased by 33 ± 4%), and non-metastatic (decreased by 14 ± 
7%) cell lines. This work coalesces two potential strategies for cancer treatment: 1) the optical 
redox ratio to assess cell metabolic features and therapy-induced changes 2) the method of 
inducing a “stress” test to identify further differences in heterogeneous cell populations. 
1. Introduction
Tumor heterogeneity is a major hallmark of cancer and has hindered the ability to create a 
ubiquitous form of successful therapy for patients [1-3]. Locoregional tumors possess a variation 
of heterogeneous cells that arise from subclonal populations, of which only the “fittest” groups 
are able to contribute to the overall phenotype [4]. The causal role of somatic mutations within 
the cell groups can lead to adverse behaviors for a particular tumor, which in turn can create 
mutability spatially and temporally. Additionally, studies have shown that these subpopulations 
can contribute to metabolic reprogramming [3, 5], metastatic potency [5, 7], treatment resistance 
[8, 9], and transient dormancy signatures [10], prolonging the duration of treatment for cancer 
patients. Despite the clinical significance of cancer heterogeneity [11], its effect on the 
differentiation of malignant and benign carcinomas has gone largely unexplored. Therefore, the 
causal relationship between heterogeneous cell populations and its genetic, phenotypic and 
metabolic figures warrants further study.  
Deranged cell metabolism is a robust driver of multifaceted cancer growth. Cancer proliferation 
and function is powered by the inherent production of lactate through anaerobic glycolysis in the 
presence of oxygen, also known as the Warburg effect [12, 13]. Bypassing mitochondrial 
respiration (OXPHOS) creates a decreased presence of reactive oxygen species (ROS) and 
induces glycosylation [14], leading to the deflection of glycolytic intermediates into the pentose 
phosphate shunt and thus synthesizing lipids, amino acids, and ROS scavengers for increased 
protection of the cellular antioxidant system [15]. Conversely, recent studies have suggested that 
the increased presence of OXPHOS [16-18] and ROS [17, 19] is directly proportional to invasive 
and metastatic potential. Tumor entities with activated oncogenes [20] and a substantial 
difference in intra/extracellular pH [21], caused by the variation in metabolic routes taken by the 
cell, can further confer metastatic behaviors. Additionally, the most common sites of metastasis 
exhibit varied metabolic programs used by metastatic cancer cells [22]. More studies related to 
these metabolic codependencies can lead the cancer community in a more direct path for 
investigating prognostic markers that portend a migratory phenotype. 
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Chance et al. were one of the first of many to assess the redox state of the cell using intrinsic 
metabolic fluorescence [23]. Within cells, flavin adenine dinucleotide (FAD) and nicotinamide 
adenine dinucleotide (NADH), electron transport chain’s cardinal acceptor and donor 
respectively, emit the only forms of autonomous fluorescence with regards to metabolism. With 
optical imaging, these fluorescent figures can be used to contribute to the optical redox ratio 
(FAD/(NADH+FAD)), an assessment of cellular metabolic activity [23]. This ratio is a basic 
indicator of the cell’s preferred metabolic pathway; for instance, as glucose is catabolized and 
used to produce adenosine triphosphate (ATP) within the cell, NADH is predominantly created 
and lowers the optical redox ratio (ORR). On the other hand, if cellular respiration is chosen for 
ATP production, then FAD is preferentially formed and hence increases the ORR. Recent reports 
have rendered the ORR to be substantial because of its sensitivity to dynamic changes in real-
time [7, 24]. With the advent of stem cell therapy and regenerative medicine, the ORR can 
associate metabolic oscillations with the type of stem cell differentiation taken (such as 
osteogenic, adipogenic, or chondrogenic pathways) [25-27] and allow scientists to exploit the 
poorly understood mechanisms of these cells, while also correlating the ORR with other 
confirmed forms of cell analysis [25]. Additionally, reports have shown that the ORR has the 
ability to detect a metabolic response to radiation or drug therapy [28-30] and differentiate breast 
cancer types with various receptor expressions [31-33]. Despite the growing number of 
publications regarding the ORR’s ability to differentiate cell type, this study will be the first of 
its kind to specifically look at the ORR of a heterogeneous breast cancer cell model with 
metastatic progression. 
In this study, we investigated the endogenous fluorescence of a cohort of heterogeneous cells 
with the ORR. The isogenic cell lines – 4T1, 4T07, 168FARN, and 67NR – originated from the 
same murine tumor [22, 34-36] and vary by metastatic ability and plasticity [36].  The ORR was 
analyzed at baseline (normal conditions) and after a short period of hypoxia to reveal a 
significant difference in metabolism between metastatic cell lines and detect varying responses 
with respect to metastatic potency. We also confirm the sensitivity of the ORR to variations in 
oxygen consumption and compare it to a metabolic flux assay in vitro. This work coalesces two 
potential strategies for cancer treatment: 1) the ORR to assess cell metabolic features and 
therapy-induced changes 2) the method of inducing a “stress” test to identify further differences 
in heterogeneous cell populations.  
 
2. Methods 
 
2.1 Cell culture and short-term hypoxia 
 
The isogenic mammary cell lines used in this study and listed in Table 1 – 4T1, 4T07, 
168FARN, and 67NR – originated from a single tumor [34] and were given to us by Dr. Fred 
Miller (Karmanos Cancer Institute, Detroit, MI). The receptor statuses for all cell lines are 
stratified as negative for estrogen (ER), progesterone (PgR), and human epidermal growth factor 
receptor 2 (HER2), commonly known as triple-negative. Cells were passaged in Dulbecco’s 
Modified Eagle’s Medium (DMEM) supplemented with 10% fetal bovine serum (FBS), 2mM L-
glutamine, 1% nonessential amino acids, and 1% penicillin-streptomycin. All cell work was done 
within ten passages.  
For the acute hypoxia experiments, a gas chamber (Biospherix, Parish, NY) was used to set the 
incubator atmosphere to .5% oxygen and 5% carbon dioxide and induce hypoxia for a total of 80 
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minutes (20 minutes to achieve desired atmosphere conditions and 60 minutes of allotted 
incubation time).  
 
 
 
Table 1. Cohort of heterogeneous murine cell lines with varying metastatic potential [7]. 
 
2.2 Seahorse metabolic flux analyzer 
 
We have previously detailed the protocol for the Seahorse assay [7]. Essentially, the Seahorse 
metabolic flux analyzer determines mitochondrial usage by measuring the pH of the cell media 
before and after assigned drugs are injected sequentially. Cell densities for the panel of cell lines 
used – 4T1, 4T07, 168FARN, and 67NR – were plated at a concentration of 7500, 10000, 12500, 
and 15000 cells per well, respectively, on the day prior to experimentation. The same cell 
densities were plated in a 96-well plate for normalization purposes [36]. The normalized oxygen 
consumption rate (n-OCR) was established as the oxygen consumption rate (OCR) divided by 
the proton production rate (PPR). 
 
2.3 Multiphoton imaging 
 
Our multiphoton microscope [7] was used to attain NADH (755 nm) and FAD (860 nm) images. 
24 hours prior to imaging, the cell lines were plated at a density of 250000 cells per well in a 6-
well plate. Three field of views per plate were taken for three plates for normoxia and one hour 
following acute hypoxia. Two of these runs were completed.  
To assess ORR sensitivity, three images of NADH and FAD (6 total) of the 4T1 cell line were 
acquired every ten minutes. After three sets of images were taken at baseline, oligomycin, an 
inhibitor of complex V of the electron transport chain (ETC), was injected and three more sets of 
images were taken. The same procedure was applied after the subsequent additions of 
carbonilcyanide p-triflouromethoxyphenylhydrazone (FCCP) and a mixture of antimycin A and 
rotenone, an uncoupler that perturbs the mitochondrial membrane potential and allows oxygen to 
be optimally consumed and an inhibitor of the ETC’s complexes I and III respectively. Figure 4 
illustrates the mitochondrial-perturbing drug effect on the ORR in more detail. Following this 
experiment, a control plate was analyzed at the same time points and exhibited no change in the 
ORR (data not shown). This was repeated for two more plates. 
 
2.4 Statistics 
 
Statistical differences of the ORR were determined using a nested, two-way analysis of variance 
test. Hypoxic effects and cell lines were attributed to be fixed effects. Statistical differences of 
each cell line were evaluated via post-hoc Tukey Honestly Significant Difference tests. 
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3. Results 
 
3.1 ORR detects changes in oxygen consumption in real-time 
 
We first established the sensitivity of the ORR. The NADH and FAD images of the 4T1 cell line 
were taken before and after a serial addition of mitochondrial-perturbing drugs (Figure 1A). We 
have plotted the ORR (Figure 1B) with respect to time and saw that the ORR mimics the changes 
seen in the n-OCR plot (Figure 1C). We ensured that these variations during the time interval 
were due to the drugs used by imaging a control plate following the experiment (data not 
shown). The ORR does detect changes in the oxygen consumption of the cell and can be 
correlated to an established in vitro metabolic flux assay [7, 24]. 
 
3.2 Heterogeneous cells exhibit significantly different ORRs based on metastatic potency at 
baseline and after acute hypoxic conditions  
 
Table 1 exhibits the varying metastatic potential of the cohort of breast cancer cell lines used. 
4T1 is able to intravasate, extravasate, and grow overt metastatic nodes within the lung, liver, 
and bone. 4T07 is not able to create metastatic nodes that grow autonomously. 168FARN does 
not have any extravasation potential, and 67NR can only form a primary tumor. 
Figure 2A exhibits the ORR images of the clonogenic cell lines. We observe an increase of the 
ORR as metastatic potential increases (not including 67NR) at baseline in Figure 2B and 2C. The 
highest ORR at normal conditions was shown in the 67NR cells. We further distinguished the 
cell lines by inducing a hypoxic stress test. 4T1 and 4T07 exhibited a significantly higher ORR 
after acute hypoxia. There was relatively no change within the 168FARN group, yet within the 
67NR cell group, we saw a significant decrease in the ORR after the hypoxic stress test. Our 
results are concordant with the n-OCR for these cell lines. 
 
3.3 Reoxygenation after hypoxic stress test creates a sentinel indicator of metastatic potential 
 
Figure 3 exhibits the difference in ORR before and after acute hypoxia for each cell group. There 
was an attrition of the ORR as metastatic potency decreased. Our statistical analysis reveals a 
significant interaction between the response to hypoxia and specific cell line. This tells us that 
hypoxia-induced reoxygenation can be potentially used to differentiate heterogeneous cell 
populations with varying metastatic potential. 
 
4. Discussion 
 
A plethora of studies have focused on aberrant cell metabolism due to its omnipresence within 
metastatic progression [7, 17, 18, 22, 36]. These reports have shown that the increasing effect of 
OXPHOS [7, 18, 36] and superoxide production [17, 19, 22] can lead to a pro-migratory 
phenotype. Our results are concordant with studies that show higher mitochondrial activity as 
metastatic potential increases [31-33]. Since the ORR can sense the varying changes in oxygen 
consumption, we can use this optical technique to detect various heterogeneous cell types.  
With regards to the sensitivity of the ORR, we see a relatively high standard deviation in Figure 
1B. Cell plates are 25 millimeters in diameter and are perfused with 1 milliliter of Seahorse 
supplemented medium. The drug delivery within the perfused media was most likely not 
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homogenized properly during experimentation. On the contrary, the Seahorse instrument is 
optimized to avoid these kinds of variation. Without the exogenous drug injections, however the 
variability of the ORR is as accurate as the Seahorse metabolic assay (Figure 2B).   
Though others have seen a lower ORR (hence a higher glycolytic phenotype) for non-metastatic 
cells, our results exhibited a significantly higher ORR for the non-metastatic 67NR cells 
compared to the other clonogenic cell lines. One report reveals that the metabolomics for the 
syngeneic panel of metastatic cells (4T1, 4T07, and 168FARN) includes Krebs cycle and 
glycolytic metabolites whereas the non-metastatic form of the panel (67NR) only had the latter 
[16], which is consistent with another set of cells with metastatic progression [37]. Hence, the 
67NR cells should have a much lower ORR than the one seen in this study. Simões et al. have 
recently shown that succinate dehydrogenase (SDH) is much lower in the 67NR than in the 4T1 
cells [36]. SDH is a major factor of OXPHOS and is the only enzyme that takes part in the Krebs 
cycle and ETC. However, the limited presence of SDH lessens the amount of NADH being 
produced by succinate in the Krebs cycle [38], increasing the ORR in the 67NR cells. We have 
shown that n-OCR (OCR/PPR) measurements have concordant trends with the ORR. Looking at 
the constituents of the n-OCR, there was a 3x increase in the 4T1’s OCR and PPR measurements 
compared to the 67NR’s, creating similar n-OCR measurements at baseline. Our Seahorse 
measurements underpins the results of others [22, 36]; The n-OCR and ORR of these cell lines 
further demonstrates the rationale for inducing a hypoxic stress test to further differentiate 
heterogeneous cell lines.  
To create a biomimetic atmosphere, we have chosen to incubate the cell lines in .5% oxygen for 
sixty minutes [39]. Tumor cells have been shown to experience short-term hypoxia (within 
minutes to days at a time) as the orientation of the tumor vasculature is being restructured due to 
neoplastic growth [40, 41]. The hypoxia-mediated response of pancreatic cells with metastatic 
progression following .5 or 2 hours of hypoxia has been shown to augment the ability to migrate, 
invade, and survive whereas longer durations of hypoxia would decrease the ability to reproduce 
and increase the amount of cell death and motility [42]. A higher presence of metastasis-driven 
cells in vivo [43, 44] and cancer stem cells [45] are prevailing with more reoccurring hypoxia 
periods. Additionally, cyclic hypoxia has been shown to present higher prognostic value than the 
conventional use of gene signatures in the clinic [46]. 
Altogether, our results established metabolic differences based on varying metastatic potential in 
the ORR for a set of heterogeneous breast cancer cell populations. A hypoxic stress test further 
differentiated metastatic from non-metastatic cells and can prove indicative of a migratory 
phenotype. For the future, we would like to assess the hypoxia-mediated responses for breast 
cancer subtypes such as PgR + and ER + cells to exploit any paradigm differences seen, similarly 
to what we have done with these triple-negative cells. Additionally, we would like to gestate a 
metastatic model of 67NR through repeated cycles of hypoxia to fully understand the putative 
factors of tumor hypoxia on metastasis.  
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Figure 1. ORR detects changes in oxygen consumption in real-time. (A) Representative NADH, FAD, and ORR 
images for the 4T1 cells are shown at 20, 60, 100, and 140 minutes following the injection of mitochondrial-
perturbing drugs. (B) Longitudinal ORR plot is shown following the subsequent addition of drugs. (C) Seahorse 
metabolic flux analyzer’s n-OCR plot is shown following the serial addition of the same drugs. All error bars denote 
the standard deviation of the mean plate value [7]. 
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Figure 2. Heterogeneous cells exhibit significantly different ORRs based on metastatic potency at baseline and after 
acute hypoxic conditions. (A) ORR images are shown for the panel of breast cancer cells used at baseline and 
following our hypoxic stress test. (B) ORR is shown for each cell line at baseline and following acute hypoxia. (C) 
n-OCR is shown for each cell line at baseline and following acute hypoxia. ** represents p < .01 and *** represents 
p < .0001. All error bars denote the standard deviation of the mean plate value [7]. 
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Figure 3. Reoxygenation after hypoxic stress test creates a sentinel indicator of metastatic potential. ORR 
differences between baseline and after acute hypoxia for all cell groups are shown. All error bars denote the standard 
deviation and were found by using this equation: !"# $ + 	 !"$ $, sd1 and sd2 denote the standard deviations of 
the cell groups at baseline and following hypoxia, respectively [7]. 
 
 
 
 
Figure 4. The mitochondrial-perturbing drug effect on the ORR. Oligomycin inhibits complex V of the ETC and 
decreases OXPHOS, enabling the decrease in ORR. FCCP perturbs the mitochondrial membrane potential and 
allows oxygen to be optimally consumed, leading to an increase in ORR. The mixture of rotenone and antimycin A 
inhibit complexes I and II of the ETC and essentially eliminates OXPHOS, decreasing the ORR [7].  
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